Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL3545369 (Epacadostat, INCB-024360, INCB024360) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
Kv11.1/HERG in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] | ||||||||
ChEMBL | Inhibition of human ERG | B | 4.4 | pIC50 | >40000 | nM | IC50 | Eur J Med Chem (2019) 179: 38-55 [PMID:31233921] |
ChEMBL | Inhibition of human ERG by fluorescence polarization assay | B | 4.44 | pIC50 | >36000 | nM | IC50 | J Med Chem (2021) 64: 11302-11329 [PMID:34292726] |
indoleamine 2,3-dioxygenase 1/Indoleamine 2,3-dioxygenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4685] [GtoPdb: 2829] [UniProtKB: P14902] | ||||||||
ChEMBL | Binding affinity to NT650-NHS fluorophore-labeled recombinant human N-terminal His-tagged IDO1 expressed in Escherichia coli measured after 10 mins by microscale thermophoresis assay | B | 5.46 | pKd | 3460 | nM | Kd | J Med Chem (2020) 63: 3047-3065 [PMID:32150677] |
ChEMBL | Enzyme Assay: Human indoleamine 2,3-dioxygenasae (IDO) with an N-terminal His tag was expressed in E. coli and purified to homogeneity. IDO catalyzes the oxidative cleavage of the pyrrole ring of the indole nucleus of tryptophan to yield N′-formylkynurenine. The assays were performed at room temperature as described in the literature using 95 nM IDO and 2 mM D-Trp in the presence of 20 mM ascorbate, 5 μM methylene blue and 0.2 mg/mL catalase in 50 mM potassium phosphate buffer (pH 6.5). The initial reaction rates were recorded by continuously following the absorbance increase at 321 nm due to the formation of N′-formlylkynurenine (See: Sono, M., et al., 1980, J. Biol. Chem. 255, 1339-1345). | B | 6.7 | pIC50 | <200 | nM | IC50 | US-9320732-B2. 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase (2016) |
ChEMBL | Inhibition of IDO1 in IFN-gamma/LPS-stimulated human whole blood assessed as decrease in kynurenine levels preincubated for 15 mins followed by IFN-gamma/LPS stimulation for overnight by LC/MS/MS analysis | B | 6.9 | pIC50 | 125 | nM | IC50 | ACS Med Chem Lett (2017) 8: 486-491 [PMID:28523098] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in Escherichia coli | B | 7.01 | pIC50 | 97 | nM | IC50 | Bioorg Med Chem Lett (2020) 30: 126901-126901 [PMID:31882299] |
ChEMBL | Inhibition of recombinant human IDO1 | B | 7.03 | pIC50 | 93 | nM | IC50 | Bioorg Med Chem Lett (2021) 52: 128373-128373 [PMID:34560264] |
ChEMBL | Inhibition of IDO1 (unknown origin) assessed as reduction in kynurenine formation using L-tryptophan as substrate by methylene blue reagent based assay | B | 7.04 | pIC50 | 91 | nM | IC50 | J Med Chem (2021) 64: 17950-17968 [PMID:34854662] |
ChEMBL | Inhibition of IDO1 (unknown origin) | B | 7.05 | pIC50 | 90 | nM | IC50 | Bioorg Med Chem Lett (2020) 30: 127159-127159 [PMID:32247733] |
ChEMBL | Inhibition of recombinant human IDO1 assessed as reduction in kynurenine production using L-tryptophan as substrate incubated for 30 mins by microplate reader analysis | B | 7.06 | pIC50 | 87.4 | nM | IC50 | Eur J Med Chem (2020) 189: 112059-112059 [PMID:31981851] |
ChEMBL | Inhibition of recombinant human GST-tagged IDO1 (1 to 404 residues) using D-Tryptophan as substrate | B | 7.11 | pIC50 | 77.8 | nM | IC50 | ACS Med Chem Lett (2018) 9: 312-317 [PMID:29670692] |
ChEMBL | Inhibition of IDO1 (unknown origin) assessed as reduction in L-kynurenine formation using L-tryptophan as substrate incubated for 30 mins by microplate spectrophotometry analysis | B | 7.12 | pIC50 | 75 | nM | IC50 | Eur J Med Chem (2020) 207: 112703-112703 [PMID:32871341] |
ChEMBL | Inhibition of human N-terminal His-tagged IDO1 expressed in Escherichia coli using D-Trp as substrate | B | 7.14 | pIC50 | 73 | nM | IC50 | ACS Med Chem Lett (2017) 8: 486-491 [PMID:28523098] |
ChEMBL | Inhibition of human N-terminal GST-tagged IDO1 expressed in Escherichia coli Rosetta(DE3) pLysS using L-tryptophan as substrate measured after 1 hr by fluorescence assay | B | 7.14 | pIC50 | 73 | nM | IC50 | ACS Med Chem Lett (2020) 11: 179-187 [PMID:32071686] |
ChEMBL | Inhibition of human IDO1 | B | 7.14 | pIC50 | 72 | nM | IC50 | Bioorg Med Chem (2019) 27: 1087-1098 [PMID:30773421] |
ChEMBL | Inhibition of N-terminal His-tagged human recombinant IDO1 expressed in Escherichia coli using D-tryptophan as substrate by methylene blue/ascorbate assay | B | 7.14 | pIC50 | 72 | nM | IC50 | J Med Chem (2015) 58: 9421-9437 [PMID:25970480] |
ChEMBL | Inhibition of IDO1 (unknown origin) using D-tryptophan as substrate by spectrophotometric analysis | B | 7.14 | pIC50 | 72 | nM | IC50 | Eur J Med Chem (2018) 143: 656-669 [PMID:29220788] |
ChEMBL | Inhibition of IDO1 (unknown origin) | B | 7.14 | pIC50 | 72 | nM | IC50 | J Med Chem (2015) 58: 8762-8782 [PMID:26207924] |
ChEMBL | Inhibition of recombinant N-terminal His-tagged human IDO1 expressed in Escherichia coli assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate | B | 7.14 | pIC50 | 72 | nM | IC50 | Eur J Med Chem (2019) 182: 111629-111629 [PMID:31445231] |
ChEMBL | Inhibition of human IDO1 | B | 7.14 | pIC50 | 71.8 | nM | IC50 | J Med Chem (2016) 59: 9760-9773 [PMID:27690429] |
ChEMBL | Inhibition of N-terminal His-tagged human IDO1 expressed in Escherichia coli assessed as reduction in conversion of D-tryptophan to N-formyl kynurenine by methylene blue dye assay | B | 7.14 | pIC50 | 71.8 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of human IDO1 incubated for 60 mins in presence of L-tryptophan by HPLC analysis | B | 7.14 | pIC50 | 71.8 | nM | IC50 | J Med Chem (2016) 59: 9760-9773 [PMID:27690429] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in Escherichia coli BL21 cells assessed as reduction in conversion of L-tryptophan to N-formyl kynurenine using L-tryptophan as substrate after 30 mins by methylene blue dye based microplate reader analysis | B | 7.15 | pIC50 | 70 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of IDO1 in human HeLa cells using L-tryptophan as substrate after 20 hrs | B | 7.15 | pIC50 | 70 | nM | IC50 | Eur J Med Chem (2019) 162: 455-464 [PMID:30469041] |
GtoPdb | - | - | 7.17 | pIC50 | 67 | nM | IC50 | J Med Chem (2009) 52: 7364-7 [PMID:19507862] |
ChEMBL | Inhibition of recombinant human N-terminus IDO1 expressed in Escherichia coli assessed as N-formylkynurenine formation using L-tryptophan as substrate measured after 180 mins by UV absorbance based assay | B | 7.17 | pIC50 | 67 | nM | IC50 | Bioorg Med Chem (2016) 24: 6194-6205 [PMID:27769672] |
ChEMBL | Inhibition of human IDO1 expressed in Escherichia coli using L-tryptophan as substrate after 1 hr by UV absorption analysis | B | 7.17 | pIC50 | 67 | nM | IC50 | Bioorg Med Chem (2019) 27: 1087-1098 [PMID:30773421] |
ChEMBL | Inhibition of IDO1 (unknown origin) assessed as reduction in kynurenine formation using L-tryptophan as substrate incubated for 60 mins by fluorescence based assay | B | 7.18 | pIC50 | 66 | nM | IC50 | Bioorg Med Chem Lett (2020) 30: 127038-127038 [PMID:32088128] |
ChEMBL | Inhibition of human IDO1 using D-Trp as substrate | B | 7.19 | pIC50 | 64.6 | nM | IC50 | Eur J Med Chem (2018) 157: 423-436 [PMID:30103191] |
ChEMBL | Inhibition of recombinant human IDO1 assessed as reduction in kynurenine formation using L-tryptophan as substrate incubated for 45 mins by microplate reader assay | B | 7.24 | pIC50 | 58 | nM | IC50 | Eur J Med Chem (2020) 188: 111985-111985 [PMID:31881488] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in Escherichia coli BL21 (DE3) using tryptophan as substrate | B | 7.33 | pIC50 | 47 | nM | IC50 | Eur J Med Chem (2021) 213: 113163-113163 [PMID:33482599] |
ChEMBL | Inhibition of human N-terminal His-tagged IDO1 expressed in Escherichia coli assessed as formation of N'-formyl-kynurenine using D-tryptophan as a substrate by methylene blue based assay | B | 7.34 | pIC50 | 46 | nM | IC50 | Eur J Med Chem (2021) 223: 113631-113631 [PMID:34147748] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in Escherichia coli BL21 cells using L-tryptophan as substrate incubated for 30 mins by methylene blue dye based microplate reader analysis | B | 7.39 | pIC50 | 40.9 | nM | IC50 | Eur J Med Chem (2019) 179: 38-55 [PMID:31233921] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 30 mins by methylene blue reagent based concurrent assay | B | 7.4 | pIC50 | 40 | nM | IC50 | Bioorg Med Chem (2021) 39: 116160-116160 [PMID:33901770] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated human HeLa cells assessed as reduction in kynurenine formation measured after 48 hrs by spectrophotometry | B | 7.45 | pIC50 | 35.76 | nM | IC50 | J Med Chem (2021) 64: 17950-17968 [PMID:34854662] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 30 mins by methylene blue reagent based assay | B | 7.52 | pIC50 | 30 | nM | IC50 | Bioorg Med Chem (2021) 39: 116160-116160 [PMID:33901770] |
ChEMBL | Inhibition of human IDO1 expressed in Escherichia coli Rosetta using tryptophan as substrate incubated for 1 hr by methylene blue based assay | B | 7.59 | pIC50 | 26 | nM | IC50 | ACS Med Chem Lett (2021) 12: 195-201 [PMID:33603965] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated human THP1 cells assessed as reduction in kynurenine productio by spectrophotometric analysis | B | 7.64 | pIC50 | 23 | nM | IC50 | Eur J Med Chem (2018) 143: 656-669 [PMID:29220788] |
ChEMBL | Inhibition of IDO1 in human HeLa cells | B | 7.7 | pIC50 | 20 | nM | IC50 | Bioorg Med Chem Lett (2020) 30: 127159-127159 [PMID:32247733] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated human HeLa cells using tryptophan as substrate measured after 48 hrs | B | 7.72 | pIC50 | 19 | nM | IC50 | Eur J Med Chem (2021) 213: 113163-113163 [PMID:33482599] |
ChEMBL | Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells assessed as reduction in kynurenine production using L-tryptophan as substrate incubated for 24 hrs | B | 7.8 | pIC50 | 16 | nM | IC50 | Eur J Med Chem (2019) 184: 111750-111750 [PMID:31610376] |
ChEMBL | Inhibition of human IDO1 expressed in HEK293/MSR cells assessed as reduction in kynurenine production incubated fro 2 days | B | 7.82 | pIC50 | 15 | nM | IC50 | Eur J Med Chem (2018) 143: 656-669 [PMID:29220788] |
ChEMBL | Inhibition of IDO1 in IFNgamma and LPS-stimulated human dendritic cells co-cultured with human T cells assessed as inhibition of T-cell proliferation in presence of soluble anti-CD3 antibody and human recombinant IL-2 incubated for 2 days | B | 7.89 | pIC50 | 13 | nM | IC50 | Eur J Med Chem (2018) 143: 656-669 [PMID:29220788] |
ChEMBL | Inhibition of recombinant human IDO1 expressed in HEK293 cells assessed as N-formylkynurenine formation by measuring kynurenine level incubated for 12 hrs by microplate reader analysis | B | 7.9 | pIC50 | 12.6 | nM | IC50 | Eur J Med Chem (2019) 179: 38-55 [PMID:31233921] |
ChEMBL | Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells using L-tryptophan as substrate incubated for 48 hrs by fluorescence assay | B | 7.9 | pIC50 | 12.5 | nM | IC50 | ACS Med Chem Lett (2020) 11: 1548-1554 [PMID:32832022] |
ChEMBL | Inhibition of IDO1 in human HeLa cells assessed as production of N-formylkynurenine using tryptophan as substrate in presence of inactivated fetal bovine serum | B | 7.9 | pIC50 | 12.5 | nM | IC50 | Bioorg Med Chem Lett (2021) 49: 128314-128314 [PMID:34391891] |
ChEMBL | Inhibition of IDO1 in human HeLa cells using tryptophan as substrate incubated for 24 hrs by RFMS assay | B | 7.96 | pIC50 | 11 | nM | IC50 | J Med Chem (2021) 64: 11302-11329 [PMID:34292726] |
ChEMBL | Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells assessed as reduction in kynurenine production incubated for 24 hrs relative to control | B | 7.99 | pIC50 | 10.3 | nM | IC50 | Bioorg Med Chem (2019) 27: 1605-1618 [PMID:30858027] |
ChEMBL | Inhibition of human IDO1 | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2021) 64: 17950-17968 [PMID:34854662] |
ChEMBL | Inhibition of human recombinant IDO1 assessed as reduction in kynurenine production using L-tryptophan incubated for 60 mins by Ehrlich's reagent based assay | B | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 651-657 [PMID:29398544] |
ChEMBL | Inhibition of IDO1 in human HeLa cells using L-tryptophan as substrate incubated for 48 hrs | B | 8 | pIC50 | 10 | nM | IC50 | Eur J Med Chem (2019) 182: 111629-111629 [PMID:31445231] |
ChEMBL | Inhibition of human IDO1 expressed in HEK293T cells assessed as reduction in N-formylkynurenine production incubated for 12 hrs by microplate reader analysis | B | 8.02 | pIC50 | 9.63 | nM | IC50 | Eur J Med Chem (2020) 189: 112059-112059 [PMID:31981851] |
ChEMBL | Inhibition of IDO1 in interferon-gamma-induced human SKOV3 cells assessed as N-formylkynurenine formation using L-tryptophan as substrate measured after 24 hrs by fluorescence assay | B | 8.1 | pIC50 | 7.9 | nM | IC50 | ACS Med Chem Lett (2020) 11: 179-187 [PMID:32071686] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated human A375 cells assessed as reduction in L-Kyn level measured after 48 hrs by HPLC analysis | B | 8.11 | pIC50 | 7.7 | nM | IC50 | J Med Chem (2020) 63: 3047-3065 [PMID:32150677] |
ChEMBL | Inhibition of IDO1 in IFN-gamma-stimulated human HeLa cells assessed as decrease in kynurenine levels after 48 hrs | B | 8.13 | pIC50 | 7.4 | nM | IC50 | ACS Med Chem Lett (2017) 8: 486-491 [PMID:28523098] |
ChEMBL | Inhibition of IFN-gamma-stimulated IDO1 activity in human HeLa cells using L-tryptophan as substrate after 48 hrs by microplate reader analysis | B | 8.15 | pIC50 | 7.1 | nM | IC50 | J Med Chem (2015) 58: 9421-9437 [PMID:25970480] |
ChEMBL | Inhibition of IFN-gamma stimulated IDO1 in human HeLa cells assessed as reduction in formation of kynurenine incubated for 48 hrs in presence of IFNgamma by microplate reader assay | B | 8.15 | pIC50 | 7.1 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of IDO1 in recombinant human IFNgamma and LPS-induced human HeLa assessed as reduction in kynurenine production incubated for 2 days by spectrophotometric analysis | B | 8.15 | pIC50 | 7.1 | nM | IC50 | Eur J Med Chem (2018) 143: 656-669 [PMID:29220788] |
ChEMBL | Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells assessed as reduction in kynurenine production incubated for 18 hrs | B | 8.15 | pIC50 | 7 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of IDO1 in IFN-gamma/LPS stimulated human THP-1 cells assessed as reduction in kynurenine production after 24 hrs | B | 8.25 | pIC50 | 5.6 | nM | IC50 | Bioorg Med Chem (2019) 27: 1605-1618 [PMID:30858027] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated human HeLa cells using L-tryptophan as substrate measured after 48 hrs | B | 8.3 | pIC50 | 5 | nM | IC50 | ACS Med Chem Lett (2021) 12: 195-201 [PMID:33603965] |
ChEMBL | Inhibition of recombinant human His-tagged IDO1 (Ala2 to Gly403 residues) expressed in Escherichia coli using tryptophan as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hr by RFMS assay | B | 8.46 | pIC50 | 3.5 | nM | IC50 | J Med Chem (2021) 64: 11302-11329 [PMID:34292726] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated human OCI-AML2 cells assessed as reduction in kynurenine production | B | 8.47 | pIC50 | 3.4 | nM | IC50 | Eur J Med Chem (2018) 143: 656-669 [PMID:29220788] |
ChEMBL | Inhibition of IFNgamma-stimulated IDO1 in human HeLa cells | B | 7.89 | pEC50 | 13 | nM | EC50 | Bioorg Med Chem Lett (2020) 30: 126901-126901 [PMID:31882299] |
ChEMBL | Inhibition of human IDO1 expressed in HEK293 cells assessed as reduction in kynurenine production after 30 mins | B | 8.06 | pEC50 | 8.74 | nM | EC50 | ACS Med Chem Lett (2018) 9: 131-136 [PMID:29456801] |
ChEMBL | Inhibition of IDO1 in IFN-gamma stimulated human HeLa cells assessed as reduction in kynurenine formation using L-tryptophan as substrate incubated for 24 hrs by UV-spectrophotometry | B | 8.1 | pEC50 | 8 | nM | EC50 | Bioorg Med Chem Lett (2020) 30: 127038-127038 [PMID:32088128] |
indoleamine 2,3-dioxygenase 1 in Human [GtoPdb: 2829] [UniProtKB: P14902] | ||||||||
GtoPdb | - | - | 7.17 | pIC50 | 67 | nM | IC50 | J Med Chem (2009) 52: 7364-7 [PMID:19507862] |
indoleamine 2,3-dioxygenase 1/Indoleamine 2,3-dioxygenase 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075294] [GtoPdb: 2829] [UniProtKB: P28776] | ||||||||
ChEMBL | Inhibition of IDO1 in mouse Panc02 cells assessed as reduction in NFK level incubated for 48 hrs by RFMS analysis | B | 7.13 | pIC50 | 74 | nM | IC50 | J Med Chem (2021) 64: 11302-11329 [PMID:34292726] |
ChEMBL | Inhibition of IDO1 in IFNgamma-stimulated mouse Panc02 cells incubated for 48 hrs by RFMS method | B | 7.13 | pIC50 | 74 | nM | IC50 | J Med Chem (2021) 64: 11302-11329 [PMID:34292726] |
indoleamine 2,3-dioxygenase 2/Indoleamine 2,3-dioxygenase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3627587] [GtoPdb: 3019] [UniProtKB: Q6ZQW0] | ||||||||
ChEMBL | Inhibition of C-terminal His6-tagged human IDO2 (14 to 420 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in conversion of L-tryptophan to N-formyl kynurenine using L-tryptophan as substrate after 30 mins by methylene blue dye based microplate reader analysis | B | 4.99 | pIC50 | 10340 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of N-terminal His-tagged human IDO2 expressed in Escherichia coli expression system | B | 6.15 | pIC50 | 710 | nM | IC50 | Eur J Med Chem (2019) 182: 111629-111629 [PMID:31445231] |
indoleamine 2,3-dioxygenase 2/Indoleamine 2,3-dioxygenase 2 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2189159] [GtoPdb: 3019] [UniProtKB: Q8R0V5] | ||||||||
ChEMBL | Inhibition of mouse IDO2 expressed in human T-REx cells using L-tryptophan as substrate after 20 hrs | B | 4.72 | pIC50 | 18900 | nM | IC50 | Eur J Med Chem (2019) 162: 455-464 [PMID:30469041] |
tryptophan 2,3-dioxygenase/Tryptophan 2,3-dioxygenase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2140] [GtoPdb: 2887] [UniProtKB: P48775] | ||||||||
ChEMBL | Uncompetitive inhibition of recombinant human TDO expressed in Escherichia coli BL21 (DE3) assessed as assessed as inhibition constant using varying concentration of L-tryptophan as substrate by Dixon plot analysis | B | 4.66 | pKi | 21700 | nM | Ki | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Uncompetitive inhibition of recombinant full length C-terminal His-tagged human TDO expressed in Escherichia coli using L-Trp as substrate after 30 mins by Dixon plot analysis | B | 4.66 | pKi | 21700 | nM | Ki | Eur J Med Chem (2018) 160: 133-145 [PMID:30321802] |
ChEMBL | Inhibition of human TDO expressed in Escherichia coli Rosetta using tryptophan as substrate incubated for 1 hr by methylene blue based assay | B | 4 | pIC50 | >100000 | nM | IC50 | ACS Med Chem Lett (2021) 12: 195-201 [PMID:33603965] |
ChEMBL | Inhibition of recombinant human TDO expressed in Escherichia coli BL21 (DE3) assessed as reduction in conversion of L-tryptophan to N-formyl kynurenine using L-tryptophan as substrate after 30 mins by methylene blue assay | B | 4.19 | pIC50 | 64500 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of recombinant full length C-terminal His-tagged human TDO expressed in Escherichia coli using L-Trp as substrate after 30 mins | B | 4.19 | pIC50 | 64500 | nM | IC50 | Eur J Med Chem (2018) 160: 133-145 [PMID:30321802] |
ChEMBL | Inhibition of human TDO expressed in human T-REx cells using L-tryptophan as substrate after 20 hrs | B | 4.6 | pIC50 | 25200 | nM | IC50 | Eur J Med Chem (2019) 162: 455-464 [PMID:30469041] |
ChEMBL | Inhibition of TDO (unknown origin) | B | 5 | pIC50 | >10000 | nM | IC50 | ACS Med Chem Lett (2020) 11: 541-549 [PMID:32292562] |
ChEMBL | Inhibition of TDO (unknown origin) assessed as reduction in L-kynurenine formation using L-tryptophan as substrate incubated for 30 mins microplate spectrophotometry analysis | B | 5 | pIC50 | >10000 | nM | IC50 | Eur J Med Chem (2020) 207: 112703-112703 [PMID:32871341] |
ChEMBL | Inhibition of N-terminal His-tagged human TDO expressed in Escherichia coli expression system | B | 5 | pIC50 | >10000 | nM | IC50 | Eur J Med Chem (2019) 182: 111629-111629 [PMID:31445231] |
ChEMBL | Inhibition of recombinant human TDO2 expressed in Escherichia coli BL21 (DE3) assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 30 mins by methylene blue reagent based concurrent assay | B | 5.46 | pIC50 | 3430 | nM | IC50 | Bioorg Med Chem (2021) 39: 116160-116160 [PMID:33901770] |
ChEMBL | Inhibition of recombinant human TDO2 expressed in Escherichia coli BL21 (DE3) assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 30 mins by methylene blue reagent based assay | B | 5.67 | pIC50 | 2120 | nM | IC50 | Bioorg Med Chem (2021) 39: 116160-116160 [PMID:33901770] |
ChEMBL | Inhibition of TDO in human U87 MG cells using L-Trp as substrate after 8 hrs | B | 6.59 | pIC50 | 260 | nM | IC50 | Eur J Med Chem (2018) 160: 133-145 [PMID:30321802] |
ChEMBL | Inhibition of human TDO transfected in HEK293 cells assessed as reduction in kynurenine production using L-tryptophan as substrate incubated for 12 hrs | B | 6.59 | pIC50 | 260 | nM | IC50 | J Med Chem (2019) 62: 9161-9174 [PMID:31580660] |
ChEMBL | Inhibition of TDO (unknown origin) expressed in HEK293 cells using L-Trp as substrate after 8 hrs | B | 6.62 | pIC50 | 242 | nM | IC50 | Eur J Med Chem (2018) 160: 133-145 [PMID:30321802] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]